Answers are grounded in this paper and cite their sources.
// Francesca De Amicis 1, 2 , Carmela Guido 1, 2 , Marta Santoro 1 , Francesca Giordano 2 , Ada Donà 1, 2 , Pietro Rizza 2 , Michele Pellegrino 2 , Ida Perrotta 3 , Daniela Bonofiglio 1, 2 , Diego Sisci 1, 2 , Maria Luisa Panno 2 , Donatella Tramontano 4 , Saveria Aquila 1, 2, * , Sebastiano Andò 1, 2, * 1 Centro Sanitario, University of Calabria, Rende, Italy 2 Department of Pharmacy, Health Science and Nutrition, University of Calabria, Rende, Italy 3 DiBEST University of Calabria, Rende, Italy 4 Department of Molecular Medicine and Medical Biotechnologies, University of Naples “Federico II”, Naples, Italy * Joint senior authors Correspondence to: Francesca De Amicis, email: francesca.deamicis@unical.it Sebastiano Andò, email: sebastiano.ando@unical.it Keywords: progesterone, Bcl-2, cell cycle arrest, pRb, p16 Received: February 03, 2016 Accepted: July 09, 2016 Published: July 23, 2016 ABSTRACT Loss of progesterone-receptors (PR) expression is associated with breast cancer progression. Herein we provide evidence that OHPg/PR-B through Beclin-1 evoke autophagy-senescence transition, in breast cancer cells. Specifically, OHPg increases Beclin-1 expression through a transcriptional mechanism due to the occupancy of Beclin-1 promoter by PR-B, together with the transcriptional coactivator SRC-2. This complex binds at a canonical half progesterone responsive element, which is fundamental for OHPg effects, as shown by site-directed mutagenesis. Beside, OHPg via non-genomic action rapidly activates JNK, which phosphorylates Bcl-2, producing the functional release from Beclin-1 interaction. This is not linked to an efficient autophagic flux, since p62 levels, marker of degradation via lysosomes, were not reduced after sustained OHPg stimulus. Instead, the cell cycle inhibitor p27 was induced, together with an irreversible G1 arrest, hallmark of cellular senescence. Specifically the increase of senescence-associated β-galactosidase activity was blocked by Bcl-2 siRNA but also by Beclin-1 siRNA. Collectively these findings support the importance of PR-B expression in breast cancer cells, thus targeting PR-B may be a useful strategy to provide additional approaches to existing therapies for breast cancer patients.
No takes yet. Share an insight, caveat, or question.
Amicis et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: